肥胖与随后的肌痛性骨髓灰质炎风险之间的关联:全国性基于人口的队列研究
Soonwook Kwon1, Ye Bin Park2, Kyung-Do Han2
1Department of Neurology, Inha University Hospital, Inha University College of Medicine, Incheon, South Korea.
Acta neurologica Belgica
|March 13, 2026
概括
肥胖与患重症肌痛症 (MG) 的风险更高有关. 这项研究发现,患有I级和II级肥胖症的个体显著增加了MG风险,强调肥胖是潜在的风险因素.
科学领域:
- 免疫学 免疫学 免疫学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 众所周知,肥胖会促进一种促炎症状态.
- 肥胖是各种自身免疫性疾病的一个既定的危险因素.
- 肥胖与肌痛性肌痛症 (MG) 风险之间的具体联系以前尚不清楚.
研究的目的:
- 调查身体质量指数 (BMI) 和随后患肌痛性硬化症 (MG) 的风险之间的关联.
主要方法:
- 一项涉及20岁以上的3,937,214名成年人的全国性队列研究使用韩国国家健康保险服务数据进行.
- 参与者被分为BMI类别:体重不足,正常,预肥胖,肥胖一级和肥胖二级.
- 考克斯的比例危险模型被用于根据BMI类别来确定MG风险的调整危险比率 (aHR).
主要成果:
- 在10年的随访期间,799人被诊断出患有MG.
- 肥胖I类 (aHR1.20) 和肥胖II类 (aHR1.88) 组与正常BMI组相比,MG的风险明显更高.
- 体重不足的男性也表现出明显增加的MG风险 (aHR 2.16).
结论:
- 肥胖与患肌痛神经衰竭的风险增加有关.
- 这些发现表明,肥胖可能是MG的潜在风险因素.
- 需要进一步的研究,以充分理解肥胖和MG之间的关系.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Myasthenia Gravis: Diagnostic Tests
3.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.0K
Disorders of the Skeletal Muscle
2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
343
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
Drug Dosing: Obese Patients
325
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325


